A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 1,201–1,300 of 3,965
Fibrotic Response to Biomaterials and all Associated Sequence of Fibrosis
Jones, K. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800196-7.00009-8 · Cited by 43
Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis
Avdeev, S. N., Айсанов, З. Р., Belevskiy, А. S., Ilkovich, M. M., Коган, Е. А., Мержоева, З. М., Petrov, D., Samsonova, M. V., Terpigorev, S. A., Трушенко, Н. В., et al. (2022) · PULMONOLOGIYA · doi:10.18093/0869-0189-2022-32-3-473-495 · Cited by 32
Commensal Oral Microbiota, Disease Severity, and Mortality in Fibrotic Lung Disease
O’Dwyer, D. N., Kim, J. S., Ma, S., Ranjan, P., Das, P., Lipinski, J. H., Metcalf, J. D., Falkowski, N. R., Yow, E. S., Anstrom, K. J., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202308-1357oc · Cited by 38
Will novel oral formulations change the management of inflammatory bowel disease?
Nielsen, O. H., Seidelin, J. B., Ainsworth, M. A., & Coskun, M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1165204 · Cited by 30
Vaccinia vaccine–based immunotherapy arrests and reverses established pulmonary fibrosis
Collins, S. L., Chan‐Li, Y., Oh, M. H., Vigeland, C. L., Limjunyawong, N., Mitzner, W., Powell, J. D., & Horton, M. R. (2016) · JCI Insight · doi:10.1172/jci.insight.83116 · Cited by 28
Oh, G., Lee, S., Karna, A., Kim, H., Shen, A., Pandit, A., Lee, S., Yang, S., & So, H. (2016) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2016.79.4.257 · Cited by 30
Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo
Ma, Z., Zhao, C., Chen, Q., Yu, C.-H., Zhang, H., Zhang, Z., Huang, W., & Shen, Z. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.10.006 · Cited by 31
Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options
Hewitt, R. J., & Maher, T. M. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00647-y · Cited by 34
Kim, J. S., Anderson, M. R., Podolanczuk, A. J., Kawut, S. M., Allison, M., Raghu, G., Stukovsky, K. H., Hoffman, E. A., Tracy, R. P., Barr, R. G., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.10.011 · Cited by 30
Self-citationZhang, T., Liu, M., Gao, Y., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111475 · Cited by 29
Liu, X., Shao, Y., Zhang, X., Ji, X., Xie, M., & Liu, H. (2021) · Acta Histochemica · doi:10.1016/j.acthis.2021.151746 · Cited by 30
Wiertz, I. A., Moll, S. A., Seeliger, B., Barlo, N. P., van der Vis, J. J., Korthagen, N. M., Rijkers, G. T., Ruven, H. J. T., Grutters, J. C., Prasse, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061940 · Cited by 32
Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis
Zhou, X., Yang, D., Kong, X., Wei, C., LvQiu, S., Wang, L., Lin, Y., Yin, Z., Zhou, Z., & Luo, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.925703 · Cited by 36
Yang, M., Wu, Y., Liu, X., Zhao, C., Li, T., Li, T.-Q., Zhang, X., Jiang, H., Mao, B., & Liu, W. Q. (2023) · Respiratory Medicine · doi:10.1016/j.rmed.2023.107329 · Cited by 32
Xu, X., Guo, Y., Luo, X., Shen, Z., Sun, Z., Shen, B., Zhou, C. L., Wang, J., Lu, J., Zhang, Q., et al. (2023) · Liver International · doi:10.1111/liv.15715 · Cited by 33
Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
Shakour, N., Karami, S., Iranshahi, M., Butler, A. E., & Sahebkar, A. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102934 · Cited by 35
Prabhu, S., McLellan, A. J. A., Walters, T. E., Sharma, M., Voskoboinik, A., & Kistler, P. M. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.08.004 · Cited by 32
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future
Staitieh, B. S., Renzoni, E. A., & Veeraraghavan, S. (2015) · Annals of Medicine · doi:10.3109/07853890.2014.991751 · Cited by 32
Exercise training in idiopathic pulmonary fibrosis
Vainshelboim, B., Fox, B. D., de Oliveira, J. J. F., & Kramer, M. R. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1121104 · Cited by 30
“[1,7–9] According to the latest American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines, pulmonary rehabilitation has only a “weak” level of recommendation for IPF patients based on the GRADE methodology for evidence quality.”
MethodAstilbin ameliorates pulmonary fibrosis via blockade of Hedgehog signaling pathway
Zhang, J., Liu, H., Song, C., Zhang, J., Wang, Y., Lv, C., & Song, X. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.03.006 · Cited by 31
Tissue-informed engineering strategies for modeling human pulmonary diseases
Bailey, K. E., Floren, M. L., D’Ovidio, T. J., Lammers, S. R., Stenmark, K. R., & Magin, C. M. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00353.2018 · Cited by 34
Mackintosh, J. A., Desai, S. R., Adamali, H. I., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.02412-2018 · Cited by 29
Vancheri, C., Sebastiani, A., Tomassetti, S., Pesci, A., Rogliani, P., Tavanti, L. M., Luppi, F., Harari, S. A., Rottoli, P., Ghirardini, A., et al. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.08.006 · Cited by 30
Wuyts, W. A., Dahlqvist, C., Slabbynck, H., Schlesser, M., Gusbin, N., Compère, C., Maddens, S., Lee, Y.-C., Kirchgaessler, K.-U., Bartley, K., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1182-z · Cited by 31
Zamparelli, S. S., Sanduzzi, A., & Bocchino, M. (2023) · Diagnostics · doi:10.3390/diagnostics13142437 · Cited by 34
“Based on this, the paramount significance of achieving an accurate and early diagnosis, along with the timely initiation of disease-specific therapy, becomes evident to alter the outcome [3,4].”
BackgroundMortality trends in idiopathic pulmonary fibrosis in Europe between 2013 and 2018
Gonnelli, F., Bonifazi, M., & Hubbard, R. (2024) · European Respiratory Journal · doi:10.1183/13993003.02080-2023 · Cited by 30
Fetal Skin Wound Healing: Key Extracellular Matrix Components and Regulators in Scarless Healing
Gomes, M., Krijnen, P. A. J., Middelkoop, E., Niessen, H. W. M., & Boekema, B. K. H. L. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.05.027 · Cited by 38
An aging bone marrow exacerbates lung fibrosis by fueling profibrotic macrophage persistence
Farhat, A., Radhouani, M., Deckert, F., Zahalka, S., Pimenov, L., Fokina, A., Hakobyan, A., Oberndorfer, F., Brösamlen, J., Hladik, A., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adk5041 · Cited by 38
Ohkouchi, S., Ono, M., Kobayashi, M., Hirano, T., Tojo, Y., Hisata, S., Ichinose, M., Irokawa, T., Ogawa, H., & Kurosawa, H. (2015) · Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s23285 · Cited by 28
Idiopathic pulmonary fibrosis: the turning point is now!
Funke, M., & Geiser, T. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14139 · Cited by 38
Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
Salih, G. N., Shaker, S. B., Madsen, H. D., & Bendstrup, E. M. (2016) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v3.32608 · Cited by 31
Plantier, L., Renaud, H., Respaud, R., Marchand-Adam, S., & Crestani, B. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122091 · Cited by 30
Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age
Shaw, J., Marshall, T., Morris, H. G., Hayton, C., & Chaudhuri, N. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.10.111 · Cited by 34
Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway
Li, H., Wang, Z., Zhang, J., Wang, Y., Yu, C., Zhang, J., Song, X., & Lv, C. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2297-3 · Cited by 27
Skandamis, A., Kani, C., Markantonis, S. L., & Souliotis, K. N. (2019) · Journal of Drug Assessment · doi:10.1080/21556660.2019.1597726 · Cited by 35
Saketkoo, L. A., Scholand, M. B., Lammi, M. R., & Russell, A. (2020) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198320904178 · Cited by 30
Lung transplantation for idiopathic pulmonary fibrosis
Pavec, J. L., Dauriat, G., Gazengel, P., Dolidon, S., Hanna, A., Feuillet, S., Pradère, P., Crutu, A., Florea, V., Boulate, D., et al. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104026 · Cited by 33
Metformin ameliorates bleomycin-induced pulmonary fibrosis in mice by suppressing IGF-1.
Xiao, H., Huang, X., Wang, S., Liu, Z., Dong, R., Song, D., & Dai, H. (2020) · PubMed Central · Cited by 40
Fibrosis following Acute Skeletal Muscle Injury: Mitigation and Reversal Potential in the Clinic
Gardner, T., Kenter, K., & Li, Y. (2020) · Journal of Sports Medicine · doi:10.1155/2020/7059057 · Cited by 39
“Associated side effects with this medication are mostly gastrointestinal and skin-related, with wound healing and bleeding issues after surgery being particularly pertinent if the patient underwent an operation [57, 58].”
BackgroundAlqalyoobi, S., Pérez, E. R. F., & Oldham, J. M. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01328-y · Cited by 33
Chronic Lung Allograft Dysfunction: Review of CT and Pathologic Findings
Byrne, D., Nádor, R. G., English, J. C., Yee, J., Levy, R. D., Bergeron, C., Swiston, J. R., Mets, O. M., Müller, N. L., & Bilawich, A.-M. (2021) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.2021200314 · Cited by 32
Campo, A., González‐Ruiz, J. M., Andreu, E. J., Alcaide, A. B., Ocón, M. D. M., de-Torres, J. P., Pueyo, J. C., Cordovilla, R., Villarón, E. M., Sanchez-Guijo, F. M., et al. (2021) · ERJ Open Research · doi:10.1183/23120541.00773-2020 · Cited by 32
Importance of chest HRCT in the diagnostic evaluation of fibrosing interstitial lung diseases
Torres, P. P. T. E. S., Rabahi, M. F., Moreira, M. A. C., Escuissato, D. L., Meirelles, G. D. S. P., & Marchiori, E. D. S. (2021) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20200096 · Cited by 42
López-Matencio, J. M. S., Gómez, M., Vicente‐Rabaneda, E. F., González-Gay, M. Á., Ancochea, J., & Castañeda, S. (2021) · Pharmaceuticals · doi:10.3390/ph14080819 · Cited by 32
Khan, F. A., Stewart, I. D., Moss, S., Fabbri, L., Robinson, K. A., Johnson, S., & Jenkins, G. R. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2091oc · Cited by 32
He, Y., Shang, Y., Li, Y., Wang, M., Yu, D., Yang, Y., Ning, S., & Chen, H. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01799-7 · Cited by 33
Liang, M., Matteson, E. L., Abril, A., & Distler, J. H. W. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221074457 · Cited by 34
Matthaiou, E. I., Sharifi, H., O’Donnell, C. T., Chiu, W., Owyang, C. G., Chatterjee, P., Turk, I., Johnston, L., Brondstetter, T. I., Morris, K., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01716-4 · Cited by 29
Plumbagin attenuates Bleomycin-induced lung fibrosis in mice
Mehdizadeh, S., Taherian, M., Bayati, P., Mousavizadeh, K., Pashangzadeh, S., Anisian, A., & Mojtabavi, N. (2022) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-022-00734-7 · Cited by 28
Angiopoietin-like 4 Is a Critical Regulator of Fibroblasts during Pulmonary Fibrosis Development
Saito, S., Kitabatake, M., Ouji-Sageshima, N., Ogawa, T., Oda, A., Nishimura, T., Nishioka, T., Fushimi, S., Hara, A., Shichino, S., et al. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0304oc · Cited by 31
Zhang, Y., Fu, J., Li, C., Chang, Y., Li, X., Cheng, H., Qiu, Y., Shao, M., Han, Y., Feng, D., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04961-y · Cited by 32
Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis
O’Dwyer, D. N., Armstrong, M. E., Kooblall, M., & Donnelly, S. C. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.988706 · Cited by 29
“With significant investment by the pharmaceutical industry, we now have two individual therapies that have been recently shown to slow disease progression [36,37].”
BackgroundBody size‐adjusted dose analysis of pirfenidone in patients with interstitial pneumonia
Uehara, M., Enomoto, N., Oyama, Y., Suzuki, Y., Kono, M., Furuhashi, K., Fujisawa, T., Inui, N., Nakamura, Y., & Suda, T. (2017) · Respirology · doi:10.1111/resp.13145 · Cited by 28
Enriched collagen solution as a pulp dressing in pulpotomized teeth in monkeys.
Fuks, A. B., Michaeli, Y., Sofer-Saks, B., & Shoshan, S. (1984) · PubMed · Cited by 31
Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl‐tRNA synthetase 1
Yoon, I., Kim, S., Cho, M., You, K. A., Son, J., Lee, C., Suh, J. H., Bae, D., Kim, J. M., Oh, S., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202216940 · Cited by 22
PGF2α signaling drives fibrotic remodeling and fibroblast population dynamics in mice
Rodríguez, L. R., Tang, S. Y., Barboza, W. R., Murthy, A., Tomer, Y., Cai, T., Iyer, S., Chavez, K., Das, U. S., Ghosh, S., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.172977 · Cited by 30
McCall, A. S., Gutor, S. S., Tanjore, H., Burman, A., Sherrill, T. P., Chapman, M., Calvi, C. L., Han, D., Camarata, J. E., Hunt, R. P., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adk8623 · Cited by 39
Analysis of Microarray-Identified Genes and MicroRNAs Associated with Idiopathic Pulmonary Fibrosis
Fan, L., Yu, X., Huang, Z., Zheng, S., Zhou, Y., Lv, H., Zeng, Y., Xu, J., Zhu, X., & Yi, X. (2017) · Mediators of Inflammation · doi:10.1155/2017/1804240 · Cited by 27
Recent advances in connective tissue disease related interstitial lung disease
Suzuki, A., Kondoh, Y., & Fischer, A. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1335600 · Cited by 30
Lassenius, M. I., Toppila, I., Pöntynen, N., Kasslin, L., Kaunisto, J., Kilpeläinen, M., & Laitinen, T. (2019) · European Clinical Respiratory Journal · doi:10.1080/20018525.2019.1702618 · Cited by 36
“Additionally, clinical studies with pirfenidone and nintedanib show that early initiation of disease modifying treatment can postpone irreversible deteriorative changes in lung function [2,12,13,15].”
BackgroundCarter, D. C., Wright, B., Jerome, W. G., Rose, J. P., & Wilson, E. J. (2020) · Journal of Nanomaterials · doi:10.1155/2020/4297937 · Cited by 27
“Currently, FDA-approved therapeutics for IPF only address factors which may improve symptoms or slow disease progression [20, 21] and many of the widely prescribed therapeutics for IPF have serious side effects which limit their effectiveness.”
BackgroundCaliskan, C., Seeliger, B., Jäger, B., Fuge, J., Welte, T., Terwolbeck, O., Freise, J., van Moorsel, C. H. M., Zhang, Y., & Prasse, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061993 · Cited by 28
Zhang, J., Chen, X., Chen, H., Li, R., Xu, P., Lv, C., Liu, B., & Song, X. (2020) · Pharmaceutical Biology · doi:10.1080/13880209.2020.1834590 · Cited by 28
“Hence, additional research needs to be done to explore new drugs to treat pulmonary fibrosis (King et al. 2014; Richeldi et al. 2014).”
BackgroundMachahua, C., Guler, S. A., Horn, M. P., Planas‐Cerezales, L., Montes‐Worboys, A., Geiser, T., Molina‐Molina, M., & Funke-Chambour, M. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2020-000827 · Cited by 29
Kindlin-2 Acts as a Key Mediator of Lung Fibroblast Activation and Pulmonary Fibrosis Progression
Zhang, P., Wang, J., Luo, W., Yuan, J., Cui, C., Guo, L., & Wu, C. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0320oc · Cited by 29
Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP)
Hino, T., Lee, K. S., Yoo, H., Han, J., Franks, T. J., & Hatabu, H. (2021) · European Journal of Radiology Open · doi:10.1016/j.ejro.2021.100336 · Cited by 28
Durheim, M. T., Bendstrup, E. M., Carlson, L., Sutinen, E., Hyldgaard, C., Kalafatis, D., Myllärniemi, M., Sköld, C. M., & Sjåheim, T. (2021) · Respirology · doi:10.1111/resp.14116 · Cited by 32
Ghosh, A., Hobbs, B. D., Yun, J. H., Saferali, A., Moll, M. R., Xu, Z., Chase, R., Morrow, J. D., Ziniti, J. P., Sciurba, F. C., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02013-w · Cited by 30
Zhang, R., Tan, Y., Yong, C., Jiao, Y., Tang, X., & Wang, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108805 · Cited by 31
Plasticity towards Rigidity: A Macrophage Conundrum in Pulmonary Fibrosis
Sari, E., He, C., & Margaroli, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911443 · Cited by 29
Oxygen Therapy for Interstitial Lung Disease: Physicians’ Perceptions and Experiences
Khor, Y. H., Goh, N. S. L., McDonald, C. F., & Holland, A. E. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201705-372oc · Cited by 31
Ogawa, K., Miyamoto, A., Hanada, S., Takahashi, Y., Murase, K., Mochizuki, S., Uruga, H., Takaya, H., Morokawa, N., & Kishi, K. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0559-17 · Cited by 28
Piotrowski, W. J., Bestry, I., Białas, A. J., Boros, P. W., Grzanka, P., Jassem, E., Jastrzębski, D., Klimczak, D., Langfort, R., Lewandowska, K. B., et al. (2020) · Advances in respiratory medicine · doi:10.5603/arm.2020.0081 · Cited by 32
Evolution and treatment of idiopathic pulmonary fibrosis
Torrisi, S. E., Kahn, N. C., Vancheri, C., & Kreuter, M. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104025 · Cited by 29
Pirfenidone in chronic hypersensitivity pneumonitis: a real-life experience.
Shibata, S., Furusawa, H., & Inase, N. (2018) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v35i2.6170 · Cited by 27
A Novel CD206 Targeting Peptide Inhibits Bleomycin Induced Pulmonary Fibrosis in MicePreprint
Ghebremedhin, A., Salam, A. B., Adu-Addai, B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.27.218115 · Cited by 27
“Pirfenidone and Nintedanib are only two FDA approved drugs for lung fibrosis [24, 25].”
BackgroundPerspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
Yang, X., Xu, Z., Hu, S., & Shen, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1111393 · Cited by 33
“However, the clinical studies had found that neither these two drugs alleviated the IPF-related symptoms nor improved the overall survival rate of IPF patients (Noble et al., 2011; King et al., 2014; Costabel et al., 2016).”
BackgroundCentral Role of CT in Management of Pulmonary Fibrosis
Chae, K. J., Hwang, H. J., Achcar, R. D., Cooley, J. C., Humphries, S. M., Kligerman, S. J., & Lynch, D. A. (2024) · Radiographics · doi:10.1148/rg.230165 · Cited by 30
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis
Volkmann, E. R., Denton, C. P., Kolb, M. R. J., Wijsenbeek-Lourens, M. S., Emson, C. L., Hudson, K. J., Amatucci, A. J., Distler, O., Allanore, Y., & Khanna, D. (2024) · European Respiratory Review · doi:10.1183/16000617.0015-2024 · Cited by 29
Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis
Jaroszewicz, J., Flisiak‐Jackiewicz, M., Lebensztejn, D. M., & Flisiak, R. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1057568 · Cited by 26
Who Cares about Preventing Acute Respiratory Distress Syndrome?
Rubenfeld, G. D. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201408-1574cp · Cited by 27
Development of Novel Agents for Idiopathic Pulmonary Fibrosis
O’Riordan, T. G., Smith, V., & Raghu, G. (2015) · CHEST Journal · doi:10.1378/chest.14-3218 · Cited by 29
Benvéniste, O., Rider, L. G., Aggarwal, R., Allenbach, Y., Benvéniste, O., Bleecker, J. D., de Groot, I., Devilliers, H., Hilton‐Jones, D., Hogrel, J., et al. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.05.014 · Cited by 28
Jing, T., Miao, X., Jiang, F., Guo, M., Xing, L., Zhang, J., Zuo, D., Lei, H., & Zhai, X. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.02.023 · Cited by 27
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis
Aryal, S., & Nathan, S. D. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1471465 · Cited by 29
Self-citationPirfenidone prevents acute kidney injury in the rat
Lima‐Posada, I., Fontana, F., Pérez‐Villalva, R., Berman-Parks, N., & Bobadilla, N. A. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1364-4 · Cited by 26
Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies
Wongkarnjana, A., Scallan, C. J., & Kolb, M. R. J. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000712 · Cited by 26
Aberrant B Cell Receptor Signaling in Naïve B Cells from Patients with Idiopathic Pulmonary Fibrosis
Neys, S. F. H., Heukels, P., van Hulst, J. A. C., Rip, J., Wijsenbeek, M. S., Hendriks, R. W., & Corneth, O. B. J. (2021) · Cells · doi:10.3390/cells10061321 · Cited by 29
“as transforming growth factor (TGF)-β, tumor necrosis factor (TNF)-α, and interleukin (IL)-6 [4,5].”
Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders
Sofias, A. M., Lorenzi, F. D., Peña, Q., Shalmani, A. A., Vucur, M., Wang, J., Kiessling, F. M., Shi, Y., Consolino, L., Storm, G., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113831 · Cited by 28
“In recent years, two small molecules, i.e., pirfenidone and nintedanib, have been approved for IPF [207,208].”
BackgroundInfluentialManagement of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
Copeland, C. R., & LANCASTER, L. H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.743977 · Cited by 35
Self-citationIntegrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis
Zheng, P., Sun, S., Wang, J., Cheng, Z. J., Lei, K. C., Xue, M., Zhang, T., Huang, H., Zhang, X. D., & Sun, B. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04094-0 · Cited by 31
Swigris, J. J., Bushnell, D. M., Rohr, K., Mueller, H., Baldwin, M., & Inoue, Y. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001167 · Cited by 30
Self-citationTargeting Chitinase 1 and Chitinase 3-Like 1 as Novel Therapeutic Strategy of Pulmonary Fibrosis
Lee, S., Lee, C.-M., Ma, B., Kamle, S., Elias, J. A., Zhou, Y., & Lee, C. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.826471 · Cited by 32
Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis
Schimmelpennink, M. C., Meek, D. B., Vorselaars, A. D. M., Langezaal, L. C. M., van Moorsel, C. H. M., van der Vis, J. J., Veltkamp, M., & Grutters, J. C. (2022) · Respiratory Research · doi:10.1186/s12931-022-02094-7 · Cited by 26
Are physicians in primary health care able to recognize pulmonary fibrosis?
Purokivi, M., Hodgson, U., Myllärniemi, M., Salomaa, E.-R. M., & Kaarteenaho, R. L. (2017) · European Clinical Respiratory Journal · doi:10.1080/20018525.2017.1290339 · Cited by 32
Evaluation and management approaches for scleroderma lung disease
Schoenfeld, S. R., & Castelino, F. V. (2017) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817713680 · Cited by 28
Rasooli, R., Rajaian, H., Pardakhty, A., & Mandegary, A. (2017) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2016.1342 · Cited by 31
Update in Chronic Lung Allograft Dysfunction
Shah, R., & Diamond, J. M. (2017) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2017.07.009 · Cited by 28
Lambers, C., Boehm, P. M., Lee, S., Ius, F., Jaksch, P., Klepetko, W., Tudorache, I., Ristl, R., Welte, T., & Gottlieb, J. (2018) · European Respiratory Journal · doi:10.1183/13993003.00503-2018 · Cited by 27
Zhang, Y., Jones, K. D., Achtar‐Zadeh, N., Green, G., Kukreja, J., Xu, B., & Wolters, P. J. (2019) · Histopathology · doi:10.1111/his.13745 · Cited by 26
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.